Business Wire·Aug 10, 2026, 2:00 AM ET

Innate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell Lymphoma

IPHA PARIS:IPH

Innate Pharma & Swedish Orphan Biovitrum (Sobi) entered a strategic partnership to initiate the TELLOMAK-3 Phase 3 study in cutaneous T-cell lymphoma (CTCL).
Innate will conduct the TELLOMAK-3 trial to support an accelerated approval filing for lacutamab in Sézary syndrome, with subsequent applications for full approvals in Sézary syndrome & mycosis fungoides.
Sobi will receive exclusive global commercialization rights upon potential accelerated approval & may assume full global development rights following positive Phase 3 results.
The transaction requires closing conditions, including the receipt of anti-trust clearance.
Sobi will pay Innate Pharma USD 75 million on closing, with Innate eligible for up to USD 40 million in near-term development milestones.
Innate may receive up to USD 465 million for the option to transfer full development rights & future regulatory & commercial milestones, plus tiered double-digit royalties on net sales.
Lacutamab is a first-in-class anti-KIR3DL2 antibody receiving Fast Track, PRIME, Orphan Drug, & Breakthrough Therapy designations for CTCL & Sézary syndrome.
The TELLOMAK-3 study is an open-label, multicenter, randomized trial in patients who failed prior systemic therapy, using progression-free survival as the primary endpoint.
Innate Pharma is a clinical-stage biotechnology company headquartered in Marseille, France, listed on Euronext Paris & Nasdaq.
Sobi is a global biopharma company with approximately 2,000 employees, listed on Nasdaq Stockholm, reporting SEK 28 billion in revenue for 2025.